DE3238984C2 - - Google Patents
Info
- Publication number
- DE3238984C2 DE3238984C2 DE19823238984 DE3238984A DE3238984C2 DE 3238984 C2 DE3238984 C2 DE 3238984C2 DE 19823238984 DE19823238984 DE 19823238984 DE 3238984 A DE3238984 A DE 3238984A DE 3238984 C2 DE3238984 C2 DE 3238984C2
- Authority
- DE
- Germany
- Prior art keywords
- progesterone
- group
- mastodynia
- breast
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 36
- 239000000186 progesterone Substances 0.000 claims description 17
- 229960003387 progesterone Drugs 0.000 claims description 17
- 210000000481 breast Anatomy 0.000 claims description 12
- 206010006298 Breast pain Diseases 0.000 claims description 9
- 208000006662 Mastodynia Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 6
- 208000030270 breast disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000004471 adenofibroma Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- -1 has the peculiarity Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8120034A FR2515041A1 (fr) | 1981-10-26 | 1981-10-26 | Medicament a base de progesterone pour le traitement des affections mammaires |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3238984A1 DE3238984A1 (de) | 1983-05-05 |
| DE3238984C2 true DE3238984C2 (enrdf_load_stackoverflow) | 1991-12-19 |
Family
ID=9263374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19823238984 Granted DE3238984A1 (de) | 1981-10-26 | 1982-10-21 | Arzneimittel auf basis von progesteron |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE3238984A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2515041A1 (enrdf_load_stackoverflow) |
| GB (1) | GB2109231A (enrdf_load_stackoverflow) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2558373B1 (fr) * | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee |
| US5744463A (en) * | 1996-06-03 | 1998-04-28 | Bair; Glenn O. | Treatment of side effects of progestins and progesterone analogues used for birth control |
| ATE279916T1 (de) | 1996-07-22 | 2004-11-15 | Renovo Ltd | Verwendung von substanzen, die die östrogen wirkung fördern, zur behandlung von wunden |
| US6056972A (en) * | 1997-02-26 | 2000-05-02 | Dimera, Llc | Method for reducing coronary artery reactivity |
| DE19908762A1 (de) * | 1999-02-18 | 2000-08-31 | Jenapharm Gmbh | Verwendung von Dienogest in hoher Dosierung |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US7968532B2 (en) | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
| EP1579856A1 (en) * | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| US7507769B2 (en) | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
| MXPA06010914A (es) * | 2004-03-22 | 2006-12-15 | Besins Int Lab | Tratamiento y prevencion de enfermedades de mama benigna con 4-hidroxi tamoxifen. |
| AU2006299833B2 (en) | 2005-10-12 | 2012-04-12 | Besins Healthcare Luxembourg Sarl | Improved testosterone gel and method of use |
| DE102008064534A1 (de) * | 2008-12-29 | 2010-07-15 | Reimers, Simon | Mobil-Aufrecht-Fahr-System |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1047518A (en) * | 1963-06-11 | 1966-11-02 | Glaxo Lab Ltd | 17ª-monoesters of 11,17,21-trihydroxy steroid compounds |
| US4136173A (en) * | 1977-01-31 | 1979-01-23 | American Home Products Corp. | Mixed xanthan gum and locust beam gum therapeutic compositions |
| DE2964471D1 (en) * | 1979-06-08 | 1983-02-17 | Toko Yakuhin Kogyo Kk | Creamy preparation containing steroid and process for the preparation thereof |
-
1981
- 1981-10-26 FR FR8120034A patent/FR2515041A1/fr active Granted
-
1982
- 1982-10-19 GB GB08229804A patent/GB2109231A/en not_active Withdrawn
- 1982-10-21 DE DE19823238984 patent/DE3238984A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| GB2109231A (en) | 1983-06-02 |
| DE3238984A1 (de) | 1983-05-05 |
| FR2515041B3 (enrdf_load_stackoverflow) | 1984-06-15 |
| FR2515041A1 (fr) | 1983-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3856018T2 (de) | Verwendung von einer Disaccharidpolysulfat-Aluminium Verbindung zur Herstellung eines Medikaments zur Behandlung von HÄMORRHOIDEN und zur Wundheilung | |
| EP0770388B1 (de) | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene | |
| DE69122464T2 (de) | Transdermal absorbierbares mittel mit morphin hydrochlorid | |
| EP0868188B1 (de) | Kit zur kontrazeption bei weiblichen säugern, bestehend aus einer kombination von gestagen und estrogen | |
| EP1310257A2 (de) | Kombination zur hormonalen Kontrazeption | |
| DE3238984C2 (enrdf_load_stackoverflow) | ||
| DE69117902T2 (de) | Progestogen als einziges Kontrazeptivum | |
| US5425948A (en) | Pharmaceutical compositions for the treatment and prevention of cutaneous and oral mucous membrane inflammations | |
| DE4344462A1 (de) | Zusammensetzung für die Empfängnisverhütung | |
| DE3621861A1 (de) | Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen | |
| DE2947742C2 (de) | Arzneimittel, enthaltend β-Cyclodextrin | |
| DE69825279T2 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
| DE3317692A1 (de) | Verwendung von metkephamid oder eines pharmazeutisch unbedenklichen salzes hiervon als analgetikum bei traechtigen weiblichen tieren und insbesondere bei schwangeren frauen | |
| EP0037488A2 (de) | Pharmazeutisches Mittel zur Heilung von entzündlichen und/oder degenerativen und/oder atrophischen Schleimhauterkrankungen | |
| DE3836862A1 (de) | Mittel zur transdermalen applikation von steroidhormonen | |
| JPH04356424A (ja) | アレルギー性皮膚炎用クリーム及びその製造方法 | |
| CH662510A5 (de) | Glycyrrhizin und einen wirkstoff enthaltendes arzneimittel. | |
| JPH04346917A (ja) | アレルギー性皮膚炎用クリーム及びその製造方法 | |
| DE4303823C2 (de) | Verwendung eines Extraktes aus Blüten von Salvia officinalis bei der Bekämpfung von Durchblutungsstörungen | |
| DE69424679T2 (de) | Zusammensetzung zur behandlung oder vorbeugung von herpes | |
| DE69827017T2 (de) | Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung | |
| DE3003036A1 (de) | Mittel zur verhinderung und beseitigung von glatzen | |
| DE69526111T2 (de) | Zusammensetzung zur behandlung von endometriose, welche ein salz eines edelmetalles und mel cum sale enthält | |
| WO2014184223A1 (de) | Mittel und verfahren zur behandlung von herpes | |
| CH644374A5 (en) | Water-soluble hydroxyflavone ethers and medicaments containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |